Research Articles
Unlocking Cancer's Code: Why JJCO's New "Cancer Genetics Report" Signals a Revolution in Oncology
Exploring the groundbreaking 'Cancer Genetics Report' section in JJCO and its impact on personalized cancer medicine in the post-sequencing age.
The Fungal Gold Rush: How Mold in Plants is Revolutionizing Cancer Treatment
Discover how endophytic fungi like Aspergillus fumigatus and Alternaria tenuissima are revolutionizing paclitaxel production for cancer treatment through sustainable biotech methods.
The Blue-Green Treasure: Unlocking Oscillatoria limosa's Healing Powers
Discover how Oscillatoria limosa from Pakistan's Jamshoro district shows remarkable antioxidant, antimicrobial, and anticancer properties.
The Hidden Pharmacy in Poplar Roots: Actinocorallia populi's Genomic Treasure Trove
Discover the pharmaceutical potential of Actinocorallia populi A251T, a rare actinomycete with extraordinary capacity to produce novel therapeutic compounds.
The Invisible Architect: How E-cadherin's Disappearance Rewrites Breast Cancer's Playbook
Exploring how E-cadherin loss in breast cancer drives invasion through methylation, mutations, and cadherin switching, with diagnostic and therapeutic implications.
The Clinical Trial Enrollment Crisis: Are State Mandates Enough to Break Down the Barriers?
Examining the effectiveness of state mandates in improving clinical trial enrollment and exploring multi-layered solutions to address systemic barriers.
The Invisible Symphony: How Biophysics Reveals Life's Hidden Mechanics
Exploring how biophysics decodes life's mysteries through physics, from DNA repair to cellular communication and beyond.
The Silent Uprising: How Apoptosis Proteins Fuel Esophageal Cancer's Deadly March
Exploring the role of apoptosis-related proteins caspase-6, caspase-9, FLIP and BNIP3 in esophageal squamous cell carcinomas (ESCC) progression and treatment.
The E2F1 Enigma: How a Tiny Protein Predicts Treatment Resistance in Advanced Multiple Myeloma
Discover how E2F1 protein serves as a biomarker for selinexor resistance in multiple myeloma patients, with implications for personalized treatment approaches.
The Great Unveiling: Biotech's IPO Resurgence of 2025
How innovation, capital, and clinical wins are fueling a banner year for biotech public listings in 2025